Clinical trials: pMN, open to volunteers
Neonatal Sepsis, Neutropenia
G-CSF In Neonatal Sepsis With Neutropenia
This study will evaluate whether adding G-CSF to standard treatment improves outcomes in newborns (0-28 days) with sepsis and neutropenia.
- Trial name
- NCT07888829
- Testing
- Granulocyte-colony stimulating factor (G-CSF), Standard Sepsis Management
- Where
- Pakistan
- Volunteers
- 52 people
- Sponsor
- University of Health Sciences Lahore
Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia
A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders
The purpose of this study is to evaluate the safety and tolerability of G-CSF dosage reduction with mavorixafor in participants with autoimmune neutropenia (AIN) and chronic idiopathic neutropenia (CIN) disorders as assessed by…
- Conditions
- Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia, Autoimmune Neutropenia, Chronic Idiopathic Neutropenia
- Trial name
- NCT07902830
- Testing
- Mavorixafor
- Volunteers
- 40 people
- Sponsor
- X4 Pharmaceuticals
Neuroblastoma
GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.
This exploratory clinical study will evaluate the efficacy and feasibility of combining a GSL synthase inhibitor with a granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with advanced or metastatic…
- Trial name
- NCT07090538
- Testing
- Eliglustat
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
pMN, IgAN
Atacicept in Multiple Glomerular Diseases
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD
- Trial name
- NCT06983028
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Vera Therapeutics, Inc.
Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy
Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia
This study aim to find the best option for children having cancer who develop low immunity state due to chemotherapy
- Conditions
- Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy, Febrile Neutropenia, Drug-Induced, G-CSF
- Trial name
- AGF-FN (NCT06988826)
- Testing
- G-CSF, Antibiotics only
- Volunteers
- 150 people
- Sponsor
- King Edward Medical University
Diamond Blackfan Anemia
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)
Gene therapy is a new possible treatment for the anemia of DBAS. Gene therapy will soon be available for patients with RPS19-mutated DBAS.
- Trial name
- NCT07186179
- Testing
- Mobilization Regimen
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
High-Risk Neuroblastoma
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
This clinical trial will evaluate the safety of chemoimmunotherapy with Naxitamab and COG-type induction chemotherapy in newly-diagnosed patients with high-risk neuroblastoma. We aim to recruit 10 patients over the next 2 years.
- Trial name
- NCT07537400
- Testing
- Naxitamab
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Shaare Zedek Medical Center
Acute Myeloid Leukemia, Stem Cell Transplantation
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
Allogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death.
- Conditions
- Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Cord Blood Stem Cell Transplantation
- Trial name
- GRACE (NCT07372885)
- Testing
- Cord blood transplantation + conditioning + granulocytes of variable days according to study design
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Manchester
Neuroblastoma
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
This is a single-arm, multicenter clinical trial conducted in patients ≥ 12 months of age with high-risk neuroblastoma in first complete response.
- Trial name
- NCT06047535
- Testing
- Naxitamab
- Volunteers
- 62 people
- Sponsor
- SciClone Pharmaceuticals